Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Interventions
Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
Drug · Combination Product
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Buffalo, New York + 1 more
Active, not recruiting Not applicable Interventional

Taking AIM at Breast Cancer

NCT04720209
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
CARE, TARE, Home-Based Stretching
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Not yet recruiting Phase 2 Interventional

Defining the Ablative Dose for Y-90 TARE

NCT07586046
Conditions
HCC - Hepatocellular Carcinoma
Interventions
Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions
Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Miami, Florida
Conditions
Hepatocellular Carcinoma
Interventions
CT Liver Perfusion, PET/CT of liver
Radiation
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

Adherence and Perspiration While Wearing Lower Limb Prostheses

NCT03900845
Conditions
Lower Extremity Amputation
Interventions
Dynamic Air Exchange - Rising Edge Design (DAE-RED), Perforated elastomeric liner, As-prescribed prosthesis
Device
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hepatoblastoma, Hepatocellular Carcinoma, Rhabdoid Tumor of Liver, Undifferentiated (Embryonal) Sarcoma of the Liver, Pediatric Liver Cancer, Liver Tumors
Interventions
Quality of Life Assessment, Transarterial Radioembolization
Behavioral · Radiation
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
0 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Wilmington, Delaware • Jacksonville, Florida
Conditions
Cancer Survivor, Central Obesity, Estrogen Receptor Positive, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Liver Cancer (Primary and Metastatic), Renal Cancer
Interventions
Not listed
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more
Recruiting Phase 2 Interventional

IIT2025-03-YANG-LIFT-HCC

NCT07489976
Conditions
Hepato Cellular Carcinoma
Interventions
STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
Drug
Lead sponsor
Ju Dong Yang
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
5-Azacitadine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Heptocellular Cancer
Interventions
Transarterial Radioembolization, Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions
Y90 TARE, PET/CT, PET/MRI
Radiation · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
SIR-Spheres microspheres (Yttrium-90 Microspheres), Gemcitabine, Cisplatin
Device · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more